The clinical yield of bronchoscopy in the management of cystic fibrosis: A retrospective multicenter study.
bronchoscopy
cystic fibrosis
sputum cultures
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
28
09
2022
received:
17
07
2022
accepted:
24
10
2022
pubmed:
1
11
2022
medline:
25
1
2023
entrez:
31
10
2022
Statut:
ppublish
Résumé
Pulmonary disease is the leading cause of morbidity and mortality in people with cystic fibrosis (pwCF). Several studies have shown no benefit for bronchoscopy and bronchoalveolar lavage (BAL) over sputum to obtain microbiological cultures, hence the role of bronchoscopy in pwCF is unclear. To analyze how bronchoscopy results affected clinical decision-making in pwCF and assess safety. A retrospective analysis of all charts of pwCF from three CF centers in Israel, between the years 2008 and 2019. We collected BAL culture results as well as sputum cultures obtained within 1 month of the BAL sample. A meaningful yield was defined as a decision to start antibiotics, change the antibiotic regimen, hospitalize the patient for treatment, or the resolution of the problem that led to bronchoscopy (e.g., atelectasis or hemoptysis). During the study years, of the 428 consecutive patient charts screened, 72 patients had 154 bronchoscopies (2.14 bronchoscopies/patient). Forty-five percent of the bronchoscopies had a meaningful clinical yield. The finding of copious sputum on bronchoscopy was strongly associated with a change in treatment (OR: 5.25, 95%CI: 2.1-13.07, p < 0.001). BAL culture results were strongly associated with a meaningful yield, specifically isolation of Aspergillus spp. (p = 0.003), Haemophilus influenza (p = 0.001). Eight minor adverse events following bronchoscopy were recorded. In this multicenter retrospective analysis of bronchoscopy procedures from three CF centers, we have shown that a significant proportion of bronchoscopies led to a change in treatment, with no serious adverse events. Our findings suggest that bronchoscopy is a safe procedure that may assist in guiding treatment in some pwCF. Future studies should evaluate whether BAL-guided decision-making may also lead to a change in clinical outcomes in pwCF.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary disease is the leading cause of morbidity and mortality in people with cystic fibrosis (pwCF). Several studies have shown no benefit for bronchoscopy and bronchoalveolar lavage (BAL) over sputum to obtain microbiological cultures, hence the role of bronchoscopy in pwCF is unclear.
AIM
OBJECTIVE
To analyze how bronchoscopy results affected clinical decision-making in pwCF and assess safety.
METHODS
METHODS
A retrospective analysis of all charts of pwCF from three CF centers in Israel, between the years 2008 and 2019. We collected BAL culture results as well as sputum cultures obtained within 1 month of the BAL sample. A meaningful yield was defined as a decision to start antibiotics, change the antibiotic regimen, hospitalize the patient for treatment, or the resolution of the problem that led to bronchoscopy (e.g., atelectasis or hemoptysis).
RESULTS
RESULTS
During the study years, of the 428 consecutive patient charts screened, 72 patients had 154 bronchoscopies (2.14 bronchoscopies/patient). Forty-five percent of the bronchoscopies had a meaningful clinical yield. The finding of copious sputum on bronchoscopy was strongly associated with a change in treatment (OR: 5.25, 95%CI: 2.1-13.07, p < 0.001). BAL culture results were strongly associated with a meaningful yield, specifically isolation of Aspergillus spp. (p = 0.003), Haemophilus influenza (p = 0.001). Eight minor adverse events following bronchoscopy were recorded.
CONCLUSIONS
CONCLUSIONS
In this multicenter retrospective analysis of bronchoscopy procedures from three CF centers, we have shown that a significant proportion of bronchoscopies led to a change in treatment, with no serious adverse events. Our findings suggest that bronchoscopy is a safe procedure that may assist in guiding treatment in some pwCF. Future studies should evaluate whether BAL-guided decision-making may also lead to a change in clinical outcomes in pwCF.
Identifiants
pubmed: 36314650
doi: 10.1002/ppul.26216
pmc: PMC10100270
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
500-506Informations de copyright
© 2022 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.
Références
J Cyst Fibros. 2012 Sep;11(5):446-53
pubmed: 22554417
Pediatr Pulmonol. 2017 Feb;52(2):182-189
pubmed: 27905200
J Pediatr. 1998 Apr;132(4):589-95
pubmed: 9580754
Eur Respir J. 2018 May 17;51(5):
pubmed: 29678944
Dtsch Arztebl Int. 2017 Jun 5;114(21):371-381
pubmed: 28625277
Am J Respir Crit Care Med. 2020 Mar 15;201(6):688-696
pubmed: 31747309
JAMA. 2011 Jul 13;306(2):163-71
pubmed: 21750293
PLoS One. 2016 Oct 6;11(10):e0164232
pubmed: 27711152
Mycopathologia. 2018 Feb;183(1):21-32
pubmed: 28762125
Am J Respir Crit Care Med. 2003 Oct 15;168(8):918-51
pubmed: 14555458
Curr Fungal Infect Rep. 2016;10(4):163-169
pubmed: 28035247
J Bronchology Interv Pulmonol. 2022 May 27;:
pubmed: 35698279
Eur Respir J. 2001 Feb;17(2):281-6
pubmed: 11334132
Am J Respir Crit Care Med. 2019 Sep 1;200(5):590-599
pubmed: 30811949
Thorax. 2001 Mar;56 Suppl 1:i1-21
pubmed: 11158709
Lancet. 2003 Feb 22;361(9358):681-9
pubmed: 12606185
Lancet Respir Med. 2018 Jun;6(6):461-471
pubmed: 29778403
Eur Respir J. 2004 Oct;24(4):631-7
pubmed: 15459143
Respir Med. 1994 Apr;88(4):313-5
pubmed: 8036296
J Cyst Fibros. 2016 Mar;15(2):147-57
pubmed: 26454351
Pediatr Pulmonol. 2001 May;31(5):383-8
pubmed: 11340685
Cochrane Database Syst Rev. 2018 Sep 17;9:CD009530
pubmed: 30221745
Sci Transl Med. 2019 Apr 3;11(486):
pubmed: 30944166
J Thorac Dis. 2017 Sep;9(Suppl 10):S1139-S1145
pubmed: 29214071
Pediatr Pulmonol. 2023 Feb;58(2):500-506
pubmed: 36314650
PLoS One. 2021 Jan 22;16(1):e0245696
pubmed: 33481845